Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer-Reference-Cited by-同舟云学术

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

Published:2020-08 Issue:8 Volume:31 Page:1001-1010
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Rugo H.S.,André F.,Yamashita T.,Cerda H.,Toledano I.,Stemmer S.M.,Jurado J.C.,Juric D.,Mayer I.,Ciruelos E.M.,Iwata H.,Conte P.,Campone M.,Wilke C.,Mills D.,Lteif A.,Miller M.,Gaudenzi F.,Loibl S.

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference12 articles.

1. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;J Natl Cancer Inst,2014

2. The prognostic value of PI3K mutational status in breast cancer: a meta-analysis;Sobhani;J Cell Biochem,2018

3. Comprehensive molecular portraits of human breast tumours;Nature,2012

4. A systematic literature review of the prevalence of PIK3CA mutations and mutation hotspots in HR+/HER2- metastatic breast cancer;Mollon;Cancer Res,2018

5. Phosphatidylinositol 3-kinase, growth disorders, and cancer;Goncalves;N Engl J Med,2018

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis;European Journal of Pharmacology;2024-11

2. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study;Journal of Clinical Oncology;2024-09-06

3. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study;ESMO Open;2024-09

4. SGLT2 inhibition improves PI3Kα inhibitor–induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials;Breast Cancer Research and Treatment;2024-08-23

5. Lessons learned from an unsuccessful decentralized clinical trial in Oncology;npj Digital Medicine;2024-08-13